Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting
February 25, 2019 08:00 ET
|
Humanigen, Inc
First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivoEnhanced anti-tumor activity, improved overall survival, and improved...
Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)
February 15, 2019 08:00 ET
|
Humanigen, Inc
Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralizationLenzilumab (an anti-GM-CSF antibody) used in...
Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’
January 03, 2019 16:05 ET
|
Humanigen, Inc
Study Demonstrates a Significant Increase in Overall Survival in MiceRobust Anti-tumor Response with No Toxicity Using EphA3 Antibody Drug Conjugate (ADC) and Radioimmunotherapy (RIT) Approaches...
Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
December 04, 2018 07:30 ET
|
Humanigen, Inc
Lenzilumab (an anti-GM-CSF antibody) in combination with CAR-T cell therapy prevents cytokine release syndrome and neuroinflammation while improving durable control of leukemic diseaseExponential...
Lenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First Edition
November 30, 2018 07:30 ET
|
Humanigen, Inc
Lenzilumab (an anti-GM-CSF antibody) in combination with CAR-T cell therapy prevents cytokine release syndrome and neuro-inflammation while improving durable control of leukemic diseaseExponential...
Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)
November 02, 2018 08:00 ET
|
Humanigen, Inc
Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T (CAR-T) Cell Therapy Prevents the Onset of Cytokine Release Syndrome, Significantly...
Humanigen Announces Positive Topline Study Results
August 20, 2018 08:00 ET
|
Humanigen, Inc
Study Demonstrates that GM-CSF Blockade in Combination with Chimeric Antigen Receptor T Cell Therapy (CAR-T) Prevents the Onset and Severity of Neurotoxicity and Cytokine Release Syndrome BURLINGAME,...
Humanigen CEO to Present at 8th Annual LD Micro Invitational
May 30, 2018 08:00 ET
|
Humanigen, Inc
BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments, today announced...
Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy
May 02, 2018 16:10 ET
|
Humanigen, Inc
Lenzilumab effectively neutralizes GM-CSF CAR-T cells maintained robust anti-tumor activity in combination with lenzilumab GM-CSF depletion by lenzilumab may increase CAR-T expansion BRISBANE,...
Humanigen Names Dr. Tarek Sahmoud as Chief Medical Officer
April 30, 2018 07:00 ET
|
Humanigen, Inc
BRISBANE, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments, today announced...